ABVC BioPharma, Inc. (NASDAQ: ABVC) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, reporting a 179% year-over-year increase in total assets to $21,062,203, up from $7,539,907 in 2024. The significant balance sheet expansion was primarily fueled by strategic acquisitions of land and development-oriented assets in Asia, with net property and equipment rising to $12,835,409 from $511,088.
As of December 31, 2025, the company reported total assets of $21.06 million, including property and equipment of $12.84 million, operating lease right-of-use assets of $1.91 million, and long-term investments of $1.88 million. Management views 2025 as a year of structural strengthening of the balance sheet and asset foundation.
ABVC has strategically licensed its core drug programs to subsidiaries and related parties to reduce direct clinical cash burn exposure while retaining licensing economics and equity participation. Its CNS pipeline was licensed to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this structure, subsidiaries and related parties handle clinical development, while ABVC reduces risk and preserves upside.
In parallel, the company is expanding its long-term infrastructure positioning in Asia through direct and subsidiary-driven land acquisitions. In Longtan District, Taoyuan, ABVC holds a 5,995.41 square meter property valued at $4.6 million as of December 31, 2025, with flexible future use potential including healthcare-related applications. In Puli Township, Nantou, a 69,230.90 square meter property was independently appraised at approximately $8.0 million as of January 30, 2026. The Puli development plan aims to establish a medicinal plant cultivation base, support pharmaceutical supply chain localization, and create an agricultural-biotech integration platform, with projected annual output value estimated between $60,000 and $360,000.
These land acquisitions reflect ABVC's evolution toward a hybrid asset model that combines intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets. The company's pipeline includes six drugs and one medical device (ABV-1701/Vitargus®), with in-licensed technology from research institutions such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.
Forward-looking statements in the press release are subject to risks and uncertainties, including those related to manufacturing, financing, competition, key personnel, and regulatory approvals. More detailed information is available in the company's filings with the SEC at http://www.sec.gov.
